Blois Joseph, Yuan Hushan, Smith Adam, Pacold Michael E, Weissleder Ralph, Cantley Lewis C, Josephson Lee
Center for Molecular Imaging Research, Massachusetts General Hospital and Harvard Medical School, Charlestown, Massachusetts 02129, USA.
J Med Chem. 2008 Aug 14;51(15):4699-707. doi: 10.1021/jm800374f. Epub 2008 Jul 17.
When the viridin wortmannin (Wm) is modified by reaction with certain nucleophiles at the C20 position, the compounds obtained exhibit an improved antiproliferative activity even though a covalent reaction between C20 and a lysine in the active site of PI3 kinase is essential to Wm's ability to inhibit this enzyme. Here we show that this improved potency results from an intramolecular attack by the C6 hydroxyl group that slowly converts these inactive prodrugs to the active species Wm over the 48 h duration of the antiproliferative assay. Our results provide a guide for selecting Wm-like compounds to maximize kinase inhibition with the variety of protocols used to assess the role of PI3 kinase in biological systems, or for achieving optimal therapeutic effects in vivo . In addition, the slow self-activation of WmC20 derivatives provides a mechanism that can be exploited to obtain kinase inhibitors endowed with physical and pharmacokinetic properties far different from man-made kinase inhibitors because they do not bind to kinase active sites.
当绿胶霉素渥曼青霉素(Wm)在C20位与某些亲核试剂反应进行修饰时,所得到的化合物表现出增强的抗增殖活性,尽管C20与PI3激酶活性位点的赖氨酸之间的共价反应对于Wm抑制该酶的能力至关重要。在此我们表明,这种增强的效力源于C6羟基的分子内攻击,在抗增殖试验的48小时期间,这种攻击会将这些无活性的前药缓慢转化为活性物质Wm。我们的结果为选择类似Wm的化合物提供了指导,以便在用于评估PI3激酶在生物系统中作用的各种方案中最大化激酶抑制,或在体内实现最佳治疗效果。此外,WmC20衍生物的缓慢自我激活提供了一种机制,可用于获得具有与人工合成激酶抑制剂截然不同的物理和药代动力学性质的激酶抑制剂,因为它们不与激酶活性位点结合。